拉利瑪治療公司
US ˙ NasdaqGM ˙ US5171251003

SecurityLRMR / Larimar Therapeutics, Inc.
InstitutionQube Research & Technologies Ltd
Latest Disclosed Ownership847,644 shares
Latest Disclosed Value $ 3,814,398
Qube Research & Technologies Ltd ownership in LRMR / Larimar Therapeutics, Inc.

On May 15, 2026 - Qube Research & Technologies Ltd filed a 13F-HR form disclosing ownership of 847,644 shares of Larimar Therapeutics, Inc. (US:LRMR) valued at $3,814,398 USD as of March 31, 2026. The entity filed a previous 13F-HR on August 14, 2024 disclosing 0 shares of Larimar Therapeutics, Inc.. The current value of the position is $2,788,749 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F LARIMAR THERAPEUTICS COM 517125100 847,644 847,644 3,814 0.0042
2024-08-14 2024-06-30 13F LARIMAR THERAPEUTICS COM 517125100 0 -89,094 -100.00 0 -100.00
2024-05-14 2024-03-31 13F LARIMAR THERAPEUTICS COM 517125100 89,094 89,094 676 0.0011
2023-08-14 2023-06-30 13F LARIMAR THERAPEUTICS COM 517125100 0 -45,782 -100.00 0 -100.00
2023-05-15 2023-03-31 13F LARIMAR THERAPEUTICS COM 517125100 45,782 45,782 207 0.0009
2021-08-13 2021-06-30 13F LARIMAR THERAPEUTICS COM 517125100 0 -11,123 -100.00 0 -100.00
2021-05-14 2021-03-31 13F LARIMAR THERAPEUTICS COM 517125100 11,123 -31,800 -74.09 163 -82.26 0.0026
2021-02-16 2020-12-31 13F LARIMAR THERAPEUTICS COM 517125100 42,923 5,278 14.02 919 60.95 0.0131
2020-11-12 2020-09-30 13F LARIMAR THERAPEUTICS COM 517125100 37,645 37,645 571 0.0081
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.